Fennec Pharmaceuticals Director Marco Maria Brughera Sells $240K of Stock
Marco Maria Brughera, Director, sold 20,000 shares of Fennec Pharmaceuticals Inc. at $12.00 a share, worth $240K in total on Nov 13, 2026. Shares held after the trade: 0 (-100.0%).
Fennec Pharmaceuticals reported a significant increase in total revenue to $19.6 million for Q3 2026, driven by PEDMARK product sales. The company achieved net income of $4.6 million compared to a net loss in the prior year, supported by a decrease in G&A expenses and improved operating margins. Cash reserves stood at $48.7 million, which management expects will be sufficient to fund operations based on the current plan.
Fennec Pharmaceuticals announced positive results from the investigator-initiated Phase 2 STS-J01 clinical study of PEDMARK in Japan for pediatric and AYA patients. The study met its primary endpoint, showing hearing loss in only 24.0% of patients compared to a historical benchmark of 56.4%, while demonstrating no interference with cisplatin antitumor activity.